Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1085 / 1092
页数：7
相关论文
共 50 条
  • [21] Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel
    Paul, Barry
    Robinson, Myra
    Symanowski, James
    Foureau, David M.
    Norek, Sarah
    Bhutani, Manisha
    Ferreri, Christopher
    Ndiaye, Ami P.
    Robinson, Jordan
    Atrash, Shebli
    Varga, Cindy
    Friend, Reed
    Pineda-Roman, Mauricio
    Smith, April
    Duda, Jessica
    Cooper, Lance
    Kitali, Amani
    Voorhees, Peter M.
    BLOOD, 2024, 144 : 7027 - 7028
  • [22] Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study
    Chang, Darryl
    Habib, Alma
    Uegel, Andrew
    Struble, Emily
    Shaikh, Hira
    Strouse, Christopher
    Green, Kimberly M.
    Mushtaq, Muhammad Umair
    Mahmoudjafari, Zahra
    Hashmi, Hamza
    Mcguirk, Joseph P.
    Khan, Abdullah Mohammad
    Abdallah, Al-Ola
    Ahmed, Nausheen
    Atrash, Shebli
    Bhutani, Manisha
    BLOOD, 2024, 144 : 2404 - 2405
  • [23] Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
    Logue, Jennifer M.
    Peres, Lauren C.
    Hashmi, Hamza
    Colin-Leitzinger, Christelle M.
    Shrewsbury, Alexandria M.
    Hosoya, Hitomi
    Gonzalez, Rebecca M.
    Copponex, Christina
    Kottra, Krista H.
    Hovanky, Vanna
    Sahaf, Bita
    Patil, Sunita
    Lazaryan, Aleksandr
    Jain, Michael D.
    Baluch, Aliyah
    Klinkova, Olga V.
    Bejanyan, Nelli
    Faramand, Rawan G.
    Elmariah, Hany
    Khimani, Farhad
    Davila, Marco L.
    Mishra, Asmita
    Blue, Brandon J.
    Grajales-Cruz, Ariel F.
    Puglianini, Omar A. Castaneda
    Liu, Hien D.
    Nishihori, Taiga
    Freeman, Ciara L.
    Brayer, Jason B.
    Shain, Kenneth H.
    Baz, Rachid C.
    Locke, Frederick L.
    Alsina, Melissa
    Sidana, Surbhi
    Hansen, Doris K.
    BLOOD ADVANCES, 2022, 6 (24) : 6109 - 6119
  • [24] US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
    Bassali, Jan
    Gould, Ian Gopal
    Kaye, James A.
    Mladsi, Deirdre
    Mehta, Jyotsna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 317 - 325
  • [25] Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    Zanwar, Saurabh
    Sidana, Surbhi
    Shune, Leyla
    Puglianini, Omar Castaneda
    Pasvolsky, Oren
    Gonzalez, Rebecca
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Davis, James A.
    Herr, Megan
    Hashmi, Hamza
    Forsberg, Peter
    Sborov, Douglas
    Anderson Jr, Larry D.
    McGuirk, Joseph P.
    Wagner, Charlotte
    Lieberman-Cribbin, Alex
    Rossi, Adriana
    Freeman, Ciara L.
    Locke, Frederick L.
    Richard, Shambavi
    Khouri, Jack
    Lin, Yi
    Patel, Krina K.
    Kumar, Shaji K.
    Hansen, Doris K.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [26] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Ferreri, Christopher
    Kalariya, Nilesh
    Anderson, Larry D., Jr.
    Afrough, Aimaz
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph
    Locke, Frederick L.
    Baz, Rachid
    Patel, Krina K.
    Alsina, Melissa
    HAEMATOLOGICA, 2024, 109 (05) : 1514 - 1524
  • [27] A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Gould, Ian
    Bassali, Jan
    Mehta, Jyotsna
    Shah, Jatin
    Mladsi, Dee Dee
    BLOOD, 2019, 134
  • [28] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bassali, J.
    Gould, I
    Mladsi, D. D.
    Kaye, J. A.
    Shah, J.
    Mehta, J.
    VALUE IN HEALTH, 2020, 23 : S33 - S33
  • [29] CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS- EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
    Wu, F.
    Zheng, X.
    Burnett, J.
    Zhou, J.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S52 - S52
  • [30] New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment
    Quesada, Stanislas
    Vaflard, Pauline
    BULLETIN DU CANCER, 2022, 109 (02) : 113 - 114
12345